文献速递类风湿关节炎

非TNFi生物制剂或托法替布治疗类风湿关节炎的恶性肿瘤风险:观察性研究Meta分析

Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies.
PubMed 文献 · Semin Arthritis Rheum · 2020-08-28

该系统综述与Meta分析纳入10项观察性研究,比较RA患者使用非TNFi生物制剂或托法替布与csDMARDs或TNFi的癌症风险。结果示利妥昔单抗、托珠单抗或托法替布未增加总体或特定癌症风险,但阿巴西普与总体癌症风险(RR 1.13,95%CI 1.02-1.24)及非黑色素瘤皮肤癌风险(RR 1.26,95%CI 1.09-1.45)轻度增加相关。

要点

  • 利妥昔单抗、托珠单抗或托法替布未增加总体或特定癌症风险。
  • 阿巴西普与总体癌症风险轻度增加相关(RR 1.13,95%CI 1.02-1.24)。
  • 阿巴西普与非黑色素瘤皮肤癌风险轻度增加相关(RR 1.26,95%CI 1.09-1.45)。

核心结论

  • 在RA患者中,与csDMARDs或TNFi相比,阿巴西普暴露与总体癌症风险轻度但统计学显著增加相关,而利妥昔单抗、托珠单抗或托法替布未显示癌症风险增加。

研究设计与样本

  • 系统检索PubMed、EMBASE和Cochrane Library并手工检索会议论文集,纳入报告RA患者使用生物制剂或托法替布且以csDMARDs或TNFi为活性对照的癌症发病率的观察性研究。
  • 共纳入10项研究,涉及超过40,587例患者(非TNFi生物制剂暴露超过87,622患者年)和2,221例患者(托法替布暴露超过4,506患者年)。

主要发现

  • 与csDMARDs或TNFi相比,利妥昔单抗(合并RR 0.87,95%CI 0.74-1.03)、托珠单抗(合并RR 0.92,95%CI 0.79-1.06)或托法替布未增加总体或特定癌症风险。
  • 与csDMARDs或TNFi相比,阿巴西普与总体癌症风险轻度增加相关(合并RR 1.13,95%CI 1.02-1.24)。
  • 与csDMARDs或TNFi相比,阿巴西普与非黑色素瘤皮肤癌风险轻度增加相关(合并RR 1.26,95%CI 1.09-1.45)。

临床怎么用

  • 临床选择非TNFi生物制剂或托法替布时,可参考利妥昔单抗、托珠单抗或托法替布未增加癌症风险的证据。
  • 使用阿巴西普的RA患者应关注总体癌症及非黑色素瘤皮肤癌风险,必要时加强皮肤监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the risk of developing cancer in patients with rheumatoid arthritis (RA) exposed to non-TNF inhibitors (TNFi) biologics or tofacitinib therapy. METHODS: Systematical search of PubMed, EMBASE and Cochrane Library plus a hand search of conference proceedings were performed. Observational studies that reported cancer incidence in patients with RA treated with biologics or tofacitinib with active comparator of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or TNFi were eligible for inclusion. The pooled relative risk (RR) and 95% confidence interval (CI) were calculated with fix-effects or random-effects model. RESULTS: Of 2,819 identified articles, a total of 10 studies involving over 40,587 patients with more than 87,622 patient-years of exposure to non-TNF inhibitors (TNFi) biologics and 2,221 patients with more than 4,506 patient-years of exposure to tofacitinib were included. Pooled analysis showed there was no increased risk of developing cancer in general or specific cancer types in RA patients receiving treatment with rituximab (pooled RR 0.87, 95% CI 0.74-1.03), tocilizumab (pooled RR 0.92, 95% CI 0.79-1.06), or tofacitinib, compared with those receiving csDMARDs or TNFi. But abatacept was associated with a slightly increased overall cancer risk (pooled RR 1.13, 95% CI 1.02-1.24) and non-melanoma skin cancer (pooled RR 1.26, 95% CI 1.09-1.45), relative to csDMARDs or TNFi in RA patients. CONCLUSION: Among RA patients, a small statistically significant increase in developing cancer was observed for abatacept exposure, while no increased cancer risk for rituximab, tocilizumab or tofacitinib, in comparison with csDMARDs or TNFi.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Xie W, Yang X, Huang H, et al. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. Semin Arthritis Rheum. 2020. PMID: 32906027. doi:10.1016/j.semarthrit.2020.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。